Last update Feb. 12, 2019
Very Low Risk
A second generation antihistamine that does not cross the blood-brain barrier, with no sedative or antimuscarinic effects (AEMPS 2015).
Oral administration or as eye drops.
Since the last update we have not found published data on its excretion in breastmilk.
Second generation antihistamines are considered safe during breastfeeding due to their lack of sedative effect as they do not cross the blood-brain barrier. When taken orally, it is recommended to use the lowest effective dose.
Until there is more information about this drug taken orally in relation to breastfeeding, safer known alternatives may be preferable, especially during the first month and in mothers of premature infants.
The small dose and poor plasma absorption of most topical ophthalmic preparations make it unlikely that significant amounts will transfer into breastmilk.
Ophthalmic epinastine reaches insignificant plasma concentration: 0.042 ng/ml (Allergan 2018 and 2012).
In ophthalmic administration, absorption can be minimized by pressing the tear duct (inner canthus of the eye) for 1 minute with a finger.
Its ophthalmic use is compatible with breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.